Table 4.
Association between isoflavone intake and MPS among breast cancer patients at 6 and 36 months postdiagnosis stratified by current tamoxifen use, the SBCSS
| Quartiles of isoflavone intake (mg/day) | No. | Multivariate OR (95% CI)a |
|||
|---|---|---|---|---|---|
| Any symptom | Hot flashes | Night sweats | Vaginal dryness | ||
| Intake at 6 months postdiagnosis (n = 4,842) | |||||
| Tamoxifen use | 2,525 | 1,549 | 1,263 | 973 | 221 |
| ≤20.0 | 644 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 634 | 1.01 (0.80–1.28) | 1.11 (0.88–1.40) | 0.93 (0.74–1.18) | 1.26 (0.84–1.88) |
| 36.47–62.63 | 640 | 1.02 (0.81–1.30) | 1.07 (0.84–1.34) | 0.98 (0.77–1.23) | 1.05 (0.69–1.58) |
| > 62.63 | 607 | 1.12 (0.88–1.43) | 1.14 (0.90–1.45) | 1.05 (0.83–1.34) | 1.16 (0.77–1.75) |
| P trend | 0.38 | 0.34 | 0.61 | 0.71 | |
| No tamoxifen use | 2,317 | 1,161 | 874 | 745 | 208 |
| ≤20.0 | 569 | 1.00 | 1.00 | 1.00 | 1.00 |
| 20.01–36.46 | 573 | 1.04 (0.82–1.33) | 1.01 (0.78–1.30) | 1.01 (0.78–1.30) | 1.28 (0.84–1.94) |
| 36.47–62.63 | 572 | 1.09 (0.85–1.39) | 1.05 (0.82–1.36) | 1.17 (0.90–1.51) | 1.19 (0.78–1.82) |
| > 62.63 | 603 | 1.08 (0.84–1.37) | 0.98 (0.76–1.26) | 1.06 (0.82–1.37) | 1.14 (0.74–1.75) |
| P trend | 0.51 | 0.94 | 0.43 | 0.67 | |
| P for interaction | 0.95 | 0.79 | 0.78 | 0.89 | |
| Weighted intake over the first 36 months postdiagnosis (n = 3,196)b | |||||
| Tamoxifen use | 2,419 | 1,564 | 1,388 | 679 | 311 |
| ≤27.28 | 615 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 564 | 1.13 (0.88–1.46) | 1.10 (0.86–1.42) | 1.11 (0.85–1.44) | 1.24 (0.87–1.75) |
| 42.23–62.86 | 623 | 1.02 (0.80–1.31) | 1.07 (0.84–1.37) | 0.99 (0.77–1.29) | 1.16 (0.82–1.62) |
| > 62.86 | 617 | 1.18 (0.92–1.52) | 1.19 (0.92–1.54) | 1.17 (0.91–1.52) | 0.96 (0.67–1.38) |
| P trend | 0.33 | 0.25 | 0.37 | 0.76 | |
| No tamoxifen use | 777 | 460 | 385 | 198 | 124 |
| ≤27.28 | 184 | 1.00 | 1.00 | 1.00 | 1.00 |
| 27.28–42.22 | 192 | 1.28 (0.82–2.00) | 1.24 (0.79–1.94) | 1.15 (0.70–1.88) | 0.84 (0.47–1.51) |
| 42.23–62.86 | 204 | 1.16 (0.75–1.81) | 1.01 (0.65–1.58) | 1.25 (0.77–2.01) | 0.97 (0.55–1.73) |
| > 62.86 | 197 | 1.21 (0.78–1.89) | 1.35 (0.86–2.12) | 1.09 (0.67–1.79) | 0.85 (0.47–1.51) |
| P trend | 0.50 | 0.33 | 0.68 | 0.72 | |
| P for interaction | 0.98 | 0.78 | 0.65 | 0.80 | |
a
Adjusted for age at diagnosis, education level (categories), parity (0, 1, 2, and ≥3), vitamin supplement use (yes/no), total meat intake (continuous), Charlson co-morbidity index (0/≥1), BMI (continuous), regular physical activity (yes/no), menopausal status, perceived quality of life (poor, average, and good), TNM stage, chemotherapy, and immunotherapy
b
Participants with unknown tamoxifen use (n = 276) were excluded